Physician profile
Thomas Nguyen
NPI 1215126800
$6,610.13
in general payments reported to CMS, 2019-2025
25 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $488 · 2021: $851 · 2022: $915 · 2023: $861 · 2024: $1,350 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,688.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,629.48 | 2019-2025 | |
| Gilead Sciences, INC. | $760.47 | 2019-2025 | Epclusa |
| Madrigal Pharmaceuticals | $666.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $523.06 | 2019-2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $313.43 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $235.03 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $234.43 | 2019-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $192.92 | 2019-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $135.00 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | |
| Pfizer INC. | $120.65 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $119.38 | 2019-2025 | |
| Genzyme Corporation | $105.82 | 2022-2025 | |
| Medtronic, INC. | $98.13 | 2022 | |
| Ardelyx, INC. | $91.62 | 2023-2025 | Ibsrela |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $70.40 | 2019-2023 | Fusion |
| Ferring Pharmaceuticals INC. | $64.15 | 2023-2025 | Rebyota, Clenpiq |
| Allergan, INC. | $41.65 | 2019 | |
| Redhill Biopharma INC. | $33.67 | 2024-2025 | Talicia |
| Boston Scientific Corporation | $20.01 | 2024 | Exalt Model D |
| Stryker Corporation | $15.16 | 2021 | |
| Capsovision, INC. | $14.18 | 2023 | Capsocam Plus |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.